drugset / Trial / NCT02750514
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Timeline
- Start
- 2016-05-09
- Primary completion
- 2020-01-29
- Completion
- 2020-01-29
Outcome
Outcome not reported
Stopped (Enrollment): “The standard of care for the patient population changed and we were unable to accrue any longer.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | LINRODOSTAT | Small molecule | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Subject | dasatinib anhydrous | Small molecule | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |